

Anticancer Research Support Association (ARSA)

2025

MOLECULAR ANALYSIS FOR PRECISION CANCER THERAPY

Assays - Challenges in
analysis, reporting and
interpretation of results-
Integration in Clinical practice

21-22 February 2025

WHO WE ARE

HOST



Dimitrios Mavroudis

Professor of Medical Oncology
Department of Medical Oncology
University General Hospital of Heraklion
Laboratory of Translational Oncology,
School of Medicine,
University of Crete

Sofia Agelaki

Professor of Medical Oncology
Department of Medical Oncology
University General Hospital of Heraklion
Laboratory of Translational Oncology,
School of Medicine,
University of Crete

John Souglakos

Professor of Medical Oncology
Department of Medical Oncology
University General Hospital of Heraklion
Laboratory of Translational Oncology,
School of Medicine,
University of Crete

Post-doctoral Researchers

Kleita Michaelidou, MSc, PhD
Maria A Papadaki, PhD
Eleni Politaki, MSc, PhD
Maria Sfakianaki, PhD
Maria Mortoglou, MSc, PhD

Research Assistant

Despoina Aggouraki, MSc


Technicians

Georgia Saloustrou

PhD students

Chara Koutoulaki, BSc
Konstantinos Vogiatzoglou, MSc
Sofia Chatziavraam, BSc

ORGANISER



WELCOME ADDRESS

We are delighted to welcome you to the second **Molecular Analysis for Precision Cancer Therapy Workshop 2025**, organized by the Laboratory of Translational Oncology in collaboration with the Department of Medical Oncology at the University General Hospital of Heraklion.

The rapidly advancing field of molecular oncology enabled the identification of novel biomarkers and therapeutic targets and transformed cancer care. In this dynamic landscape, the role of medical oncologists has expanded significantly. Nowadays, oncologists must possess a robust understanding of the molecular mechanisms of disease and of advanced analytical methods to effectively interpret current knowledge into effective cancer treatment plans.

This year's workshop is designed to address these needs, featuring a comprehensive program tailored specifically for young oncologists and researchers. Participants will gain valuable insights into key cancer genetics concepts and tumor profiling approaches while exploring cutting edge methods in biomarker testing and their clinical applications. Additionally, the program will delve into transformative innovations such as tumor-agnostic therapies and antibody-drug conjugates (ADCs), highlighting their critical roles in shaping the evolving landscape of precision oncology.

We look forward to a workshop filled with opportunities for knowledge-sharing and the development of valuable collaborative networks.

Prof. Sofia Agelaki
Prof. Dimitrios Mavroudis

MOLECULAR
ANALYSIS
FOR PRECISION
CANCER THERAPY

The Laboratory of Translational Oncology, has been established at the Faculty of Medicine, University of Crete (UoC) and operates in close collaboration with the Department of Medical Oncology, University General Hospital of Heraklion to bridge translational and clinical research activities.

The Department of Medical Oncology (DMO) is the reference center for patients with cancer for the area of Crete, Greece, since it receives approximately 1.000 new cancer patients per year and follows more than 10.000 cancer patients. The mission of the DMO is to provide clinical care to patients with cancer, to perform basic and clinical research, and to provide education and training to the next generation of scientists who are focused on the biology and treatment of cancer.

In the Laboratory of Translational Oncology (LTO) clinical and translational researchers and clinical oncologists interact, collaborate, and pool their expertise towards advancing cancer care and research. The Laboratory has all the equipment needed for its research activities aiming for a better understanding of the molecular mechanisms underlying cancer development and progression and for the development of novel issue and liquid biopsy-based prognostic and predictive biomarkers to advance precision medicine in Oncology.

LTO is part of the Hellenic Molecular Oncology Network (EDIMO), with the aim to enhance the prevention, diagnosis, and treatment of cancer patients and to develop new techniques for personalizing health care services offered to cancer patients.

LTO has actively participated in several EU-funded projects, as well as in National funded research projects.



GENERAL INFORMATION




Workshop Venue

Institute of Molecular Biology and Biotechnology of the Foundation for Research and Technology Hellas (IMBB-FORTH)

Organised by Anticancer Research Support Association (ARSA), 21-22 February 2025

TARGET AUDIENCE

Oncology Fellows/Residents
Researchers and others involved in the care of cancer patients.



MOLECULAR
ANALYSIS
FOR PRECISION
CANCER THERAPY

CME Accreditation

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s).

EACCME
European Accreditation
Council for Continuing
Medical Education



LIST OF PARTICIPANTS

- A. M. Abajo Guijarro Regional Medical Affairs Director Oncology, Daiichi Sankyo Europe
 S. Agelaki Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete
- D. Aggouraki MSc, Research Assistant, Laboratory of Translational Oncology, School of Medicine, University of Crete
- N. Androulakis Head Department of Medical Oncology, General Hospital of Heraklion "Venizeleio"
 S. Baritaki Associate Professor of Experimental Oncology, School of Medicine, University of Crete
- I. Bompolaki Medical Oncologist, General Hospital of Chania "Agios Georgios"
 A. Boukouris Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- V. Bozionelou Medical Oncologist, University General Hospital of Heraklion
 E. Chatzaki Professor, Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Greece
- S. Chatziavraam PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete
- P. Economopoulou MD, PhD Consultant Medical Oncologist, Attikon University Hospital
 F. Fostira PhD, Clinical Laboratory Geneticist, NCSR "Demokritos"
 C. Fotsitzoudis Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- M. Georgiadou Medical Oncologist, University General Hospital of Heraklion
 S. Joosse Assoc. Professor, Head of research group, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
- K. Kalbakis Medical Oncologist, University General Hospital of Heraklion
 A. Kalykaki Medical Oncologist, University General Hospital of Heraklion
 M. Kamaratou Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- N. Karachaliou Medical Director, Global Clinical Development, Merck KGaA, Darmstadt, Germany
 P. Karadaglis Medical Oncologist, "Agios Loukas" Clinic
 I. Keklikoglou Assistant Professor, Department of Biology, University of Crete
 E. Kontopodis Medical Oncologist, General Hospital of Heraklion "Venizeleio"
 G. Koronakis Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- Ch. Koutoulaki PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete
- A. Koutsopoulos Professor of Pathological Anatomy, Medical School, University of Crete, University General Hospital of Heraklion
- A. Kyriakidou Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- E. Linardaki Researcher, Human Genetics & Precision Medicine, Foundation for Research and Technology - Hellas (FORTH)
- D. Lydaki Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- A. Magklara Associate Professor of Clinical Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina
- A. Mala Medical Oncologist, University General Hospital of Heraklion
 S. Manolakou Medical Oncologist, cooperatior IASIS General Clinic (Chania), outpatient office in Chania and Rethymno, Crete
- D. Mavroudis Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete
- D. Mauri Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Ioannina, School of Medicine, University of Ioannina
- K. Michaelidou Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
- M. Mortoglou Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
- D. Nasi Medical Oncologist. General Anticancer Hospital of Kifisia "Agiou Anargiroi"
 M. Papadaki Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
- M. Papadakis Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- E. Papadopoulou PhD, International Laboratory Director, Genekor Medical S.A
 F. Papageorgiou Biologist, PhD, Diagnostics Lead Oncology AstraZeneca Greece
 D. Papanikolaou MSc, PHD, FEBU (Urol) Urologist
 E. Perdikouri Medical Oncologist, General Hospital of Volos
 E. Politaki Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
- M. Rovithi Medical Oncologist, General Hospital of Agios Nikolaos, Crete
 A. Saetta Professor, First Department of Pathology, Medical School, National and Kapodistrian University of Athens
- E. Saloustrous Associate Professor, General University Hospital of Larissa
 G. Saloustrou Technician, Laboratory of Translational Oncology, School of Medicine, University of Crete
 M. Sfakianaki Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete
- J. Souglakos Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete
- A. Spathis PhD, SCYM(ASCP), Biologist, Scientific Associate, 2nd Laboratory of Pathological Anatomy, Attikon University General Hospital, Medical School, National and Kapodistrian University of Athens (NKUA)
- I. Stoupis Medical Oncologist, General Hospital of Heraklion "Venizeleio"
 C. Stratakis Director (Researcher A'), Human Genetics & Precision Medicine, Foundation for Research and Technology - Hellas (FORTH)
- K. Svolianopoulos Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- P. Theodoropoulos Professor of Biochemistry, School of Medicine, University of Crete
 K. Thomopoulou MD, MSc, PhD, Medical Oncologist, Hygeia Hospital, Athens
 G. Tsaknakis Post-doctoral Researcher, Haemopoiesis Research Laboratory, School of Medicine, University of Crete
- A.M. Tsimberidou MD, PhD, FASCO, FAAAS, Professor, Department of Investigational Cancer Therapeutics, Katherine Russell Dixie Distinguished Endowed Professor, MD Anderson Cancer Center, University of Texas
- F. Tsokanos Senior Scientist, Translational ADME & Safety Science, Daiichi Sankyo Europe
 E. Tzagkaraki Post-doctoral Researcher, DIGENIA, Human Genetics & Precision Medicine, Foundation for Research and Technology - Hellas (FORTH)
- L. Vamvakas Medical Oncologist, University General Hospital of Heraklion
 N. Vardakis Medical Oncologist, University General Hospital of Heraklion
 M. Vasilakopoulou Consultant Medical Oncologist, United Lincolnshire Hospitals, UK
 K. Vogiatzoglou PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete
- E. Vorgia Post-doctoral Researcher, DIGENIA, Human Genetics & Precision Medicine, Foundation for Research and Technology - Hellas (FORTH)
- M. Yerolatsite Oncology Resident, University Hospital of Ioannina, Ioannina, Greece
 G. Zarkavelis Medical Oncologist, University Hospital of Ioannina, Ioannina, Greece
 C. Zioudas Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
- V. Zoumpourlis Research Director, National Hellenic Research Foundation (NHRF)

Meeting at Auditorium "Georgios Lianis", FORTH Main Building

08:30 - 09:00 Welcome

09:00 - 10:00 **Introduction to Basics** D. Mauri, D. Mavroudis

- 09:00 - 09:30 • Historical retrospection in the research of the genetic basis of cancer **V. Zoumpourlis**
- 09:30 - 10:00 • The hallmarks of cancer **I. Keklikoglou**

10:00 - 10:30 **Keynote Lecture** P. Theodoropoulos, D. Mauri
• Cancer stem cells and Precision Oncology **S. Baritaki**

10:30 - 12:00 **Currently available sequencing technologies for the Identification of Targetable Molecular Alterations in Cancer** A. Saetta, A. Magklara

- 10:30 - 10:45 • Types of molecular alterations and their relevance in oncology **K. Michaelidou**
- 10:45 - 11:00 • Next Generation Sequencing (terminology, platforms, chemistry) **G. Tsaknakis**
- 11:00 - 11:20 • Analysis of sequencing results: Biological and clinical classification of genetic variants **E. Tzagkaraki**
- 11:20 - 11:35 • Quality assessment of NGS testing **F. Papageorgiou**
- 11:35 - 12:00 Discussion

12:00 - 12:30 Coffee Break

day 1 Friday

February/2025



12:30 - 13:30 **Tumor Sequencing in the clinic** E. Linardaki, A. Magklara

- 12:30 - 12:45 • The NGS report: structure and minimal content requirements **A. Saetta**
- 12:45 - 13:05 • Recommendations on the use of NGS for patients with metastatic cancer in 2024 **I. Stoupis**
- 13:05 - 13:20 • The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) **M. Georgiadou**
- 13:20 - 13:30 Discussion

13:30 - 14:00 **Keynote Lecture** D. Mavroudis
• The Implementation of Precision Oncology in HealthCare **C. Stratakis**

14:00 - 15:00 **Lunch break**

15:00 - 16:15 **Liquid Biopsy in the Clinic** E. Chatzaki, S. Agelaki

- 15:00 - 15:20 • Recommendations on the use of ctDNA analysis in clinical decision-making **G. Zarkavelis**
- 15:20 - 15:40 • Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop **S. Agelaki**
- 15:40 - 16:00 • Clinical significance of circulating tumor cells (CTCs) in patients with solid tumors **M. Papadaki, S. Chatziavraam**
- 16:00 - 16:15 Discussion

16:15 - 17:05 **Keynote Lectures** S. Agelaki, A. Chatzaki

- 16:15 - 16:45 • Circulating Tumor DNA: Advances, Pitfalls and Opportunities **S. Joesse**
- 16:45 - 17:05 • Analysis of circulating tumor DNA in early breast cancer: methodologies and clinical utility **A. Magklara**

17:05 - 17:15 **Coffee break**

Workshop

17:15 - 19:30 **How to read an NGS report: Tips for oncologists in clinical practice** A. Saetta, A. Magklara, S. Agelaki

Trainers: G. Zarkavelis, I. Papadopoulou, E. Tzagkaraki, E. Vorgia, K. Michaelidou, K. Svoliantopoulos, Ch. Zioudas

Organizing Team: K. C. Fotsitzoudis, M. Kamaratou, A. Kyriakidou, D. Lydaki

Trainees: S. Chrysoglou, M. Giannakakou, Ch. Karachalios, V. Keramisanou, V. Kolintzikis, E. Koustas, K. Lallas, Ch. Laspa, E. Marton, A. Michas, M. Moutafi, N. Syrigos, S. Talagani, J. Trontzas, A. Svarna, V. Tzouda, E. Zazas, M. Yerolatsite

- 09:00 - 10:15 **Targeting hormone receptors in cancer (I)**
E. Saloustros, K. Kalbakis
- 09:00 - 09:20 • Advances in Estrogen Receptor Signaling and Biology
K. Thomopoulou
- 09:20 - 09:40 • Personalizing therapy for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer M. Vasilakopoulou
- 09:40 - 10:00 • Next generation anti-estrogen agents under development A. Mala
- 10:00 - 10:15 Discussion
- 10:15 - 11:15 **Targeting hormone receptors in cancer (II)**
N. Androulakis, N. Vardakis
- 10:15 - 10:35 • Current advances in targeting AR: Biology of the receptor and the importance of ARI's structure D. Papanikolaou
- 10:35 - 11:00 • ADTs in castration sensitive metastatic prostate cancer therapy: main efficacy results E. I. Perdikouri
- 11:00 - 11:15 Discussion
- 11:15 - 11:45 **Keynote Lecture** D. Mavroudis
Unlocking the potential of ADCs A. M. Abajo Guijarro, F. Tsokanos
- 11:45 - 12:15 **Coffee Break**

day 2 Saturday

February/2025

- 12:15 - 13:30 **Tumor-agnostic therapeutics: an expanding landscape**
P. Economopoulou, I. Bompolaki
- 12:15 - 12:35 • Tumor-agnostic targets and clinical targeting (I): NTRK inhibitors, BRAF V600E, HER2 A. Boukouris
- 12:35 - 12:55 • Tumor-agnostic targets and clinical targeting (II): RET fusions, TMB, dMMR S. Manolakou
- 12:55 - 13:15 • ESMO Tumor-Agnostic Classifier and Screener (ETAC-S) M. Rovithi
- 13:15 - 13:30 Discussion
- 13:30 - 14:30 **Rare Targets: ALK** L. Vamvakas, E. Kontopodis, A. Koutsopoulos
- 13:30 - 13:50 • Testing for ALK rearrangements: challenges and pitfalls A. Spathis
- 13:50 - 14:10 • Key factors that determine treatment choice D. Nasi
- 14:10 - 14:30 • Management of adverse drug reactions with ALK inhibitors P. Karadaglis
- 14:30 - 15:30 **Lunch break**
- 15:30 - 16:20 **Tumor-agnostic therapies: A paradigm shift in oncology**
S. Agelaki, A. Koutsopoulos
- 15:30 - 15:55 • Challenges in tissue agnostic therapeutics N. Karachaliou
- 15:55 - 16:20 • Tumor-agnostic oncology: transforming clinical trial design A. Tsimberidou
- 16:20 - 16:30 **Discussion and Conclusions**
- 16:30 - 18:00 **Molecular tumor board: Interesting Cases**
G. Zarkavelis, A. Saetta, F. Fostira
- 16:30 - 16:48 • CASE1: A patient with VHL mutant paraganglioma D. Lydaki
- 16:48 - 17:06 • CASE2: A patient with colorectal cancer and MUTYH-Associated Polyposis M. Papadakis
- 17:06 - 17:24 • CASE3: Loss of heterozygosity in a patient with sarcoma M. Yerolatsite
- 17:24 - 17:42 • CASE4: A patient with an exon 20 EGFR mutation M. Kamaratou
- 17:42 - 18:00 Discussion

Workshop

- 18:00 - 19:30 **Organizing Team:** K. C. Fotsitzoudis, G. Koronakis, A. Kyriakidou, M. Papadakis, K. Svoliantopoulos, Ch. Zioudas

Trainees: S. Chrysoglou, M. Giannakakou, Ch. Karachalios, V. Keramisanou, V. Kolintzikis, E. Koustas, K. Lallas, Ch. Laspa, E. Marton, A. Michas, M. Moutafi, N. Syrigos, S. Talagani, J. Trontzas, A. Svarna, V. Tzouda, E. Zazas, M. Yerolatsite

Open discussion with participants

2025

Laboratory of Translational Oncology, University of Crete, Greece

INFO: <https://oncopog.com>

CONTACT: protypoevents@gmail.com

Anticancer Research Support Association (ARSA)

